BioSig Technologies Inc. (NASDAQ:BSGM) Surging After Pure System Successful Trials
BioSig Technologies Inc. (NASDAQ:BSGM) has inched a step closer to revolutionizing how physicians detect, measure, digitize record and store electrocardiographic and intracardiac signals for patients. In partnership with Professor John Miller and r. Mithilesh K. Das, MBBS, the company has conducted successful trials of its Pure EP System at the Indiana University School of medicine.
Pure System Trials
According to Professor Miller, Pure System proved to be reliable in the detection of clear signals from the normal conduction pathway during ablation, normally obscured by noise on standard recordings. The clarity of the signal according to the professor made a vast difference in the application of ablation energy to an abnormal pathway.
Pure System is a computerized system designed to acquire digitize, amplify filter, measure, record and store electrocardiographic as well as intracardiac signals. The system seeks to minimize noise and artefacts to acquire high fidelity cardiac signals. High fidelity signals increase the diagnostic value of signals.
With the positive trial results, Pure System is slowly panning out to be a reliable system when conducting procedures on parents with atrial fibrillation as well as atrioventricular nodal reentry tachycardia.
“We are honored to be able to work with Dr. Miller and Indiana University as one of the first centers of excellence to conduct patient cases with our PURE EP(tm) System. We have tremendous respect for Dr Miller and his team at IU School of Medicine for their collective achievements in clinical electrophysiology and look forward to building upon their findings during this pivotal phase,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies.
Shares of BioSig technologies have been on an impressive run as investors react to the milestones achieved on the development of the Pure System. The stock is already up by more than 80% for the year and showing no signs of slowing down. As it stands is likely to continue powering high in the market, as investors remain optimistic about its long-term prospects with the Pure System in the fold.
The stock could spike even higher as BioSig moves to make a presentation entitled ‘Evaluation of Real-Time Catheter Tissue Contact Using Unipolar Intracardiac Signal Morphology’. The company has been accepted to the 41st International Engineering in Medicine and Biology Conference set to take place in Berlin Germany between June 23 and July 27, 2019.
BioSig is to discuss the most challenging objectives during electrophysiology studies in a bid to find ways of achieving and maintaining optimal contract between the catheter and myocardial tissue, the manuscript will contain results of a study evaluating the intracardiac morphology signals.
BioSig joins a number of medical technology companies looking to revitalize the global multi-lead Electrocardiographic machines market to cater to the rising ageing population and an increase in cardiovascular diseases. A study by Million Insights indicates that the global interventional Cardiology market is poised to grow to $25 billion by 2021.
BioSig on its part is developing a proprietary biomedical signal-processing platform to address the $4.6 billion electrophysiology marketplace.